» Articles » PMID: 37654789

Cooperation Between Neurovascular Dysfunction and Aβ in Alzheimer's Disease

Overview
Specialty Molecular Biology
Date 2023 Sep 1
PMID 37654789
Authors
Affiliations
Soon will be listed here.
Abstract

The amyloid-β (Aβ) hypothesis was once believed to represent the pathogenic process of Alzheimer's disease (AD). However, with the failure of clinical drug development and the increasing understanding of the disease, the Aβ hypothesis has been challenged. Numerous recent investigations have demonstrated that the vascular system plays a significant role in the course of AD, with vascular damage occurring prior to the deposition of Aβ and neurofibrillary tangles (NFTs). The question of how Aβ relates to neurovascular function and which is the trigger for AD has recently come into sharp focus. In this review, we outline the various vascular dysfunctions associated with AD, including changes in vascular hemodynamics, vascular cell function, vascular coverage, and blood-brain barrier (BBB) permeability. We reviewed the most recent findings about the complicated Aβ-neurovascular unit (NVU) interaction and highlighted its vital importance to understanding disease pathophysiology. Vascular defects may lead to Aβ deposition, neurotoxicity, glial cell activation, and metabolic dysfunction; In contrast, Aβ and oxidative stress can aggravate vascular damage, forming a vicious cycle loop.

Citing Articles

Olfactory dysfunction as potential biomarker in neurodegenerative diseases: a narrative review.

De Cleene N, Schwarzova K, Labrecque S, Cerejo C, Djamshidian A, Seppi K Front Neurosci. 2025; 18():1505029.

PMID: 39840019 PMC: 11747286. DOI: 10.3389/fnins.2024.1505029.


Neuropathology and neuroinflammation in Alzheimer's disease via bidirectional lung-brain axis.

Lu J, Li C, Wang J, Wang Y Front Aging Neurosci. 2024; 16:1449575.

PMID: 39280699 PMC: 11392776. DOI: 10.3389/fnagi.2024.1449575.

References
1.
Yang A, Stevens M, Chen M, Lee D, Stahli D, Gate D . Physiological blood-brain transport is impaired with age by a shift in transcytosis. Nature. 2020; 583(7816):425-430. PMC: 8331074. DOI: 10.1038/s41586-020-2453-z. View

2.
Winkler E, Nishida Y, Sagare A, Rege S, Bell R, Perlmutter D . GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci. 2015; 18(4):521-530. PMC: 4734893. DOI: 10.1038/nn.3966. View

3.
Shinohara M, Tachibana M, Kanekiyo T, Bu G . Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies. J Lipid Res. 2017; 58(7):1267-1281. PMC: 5496044. DOI: 10.1194/jlr.R075796. View

4.
Zhou B, Lu J, Siddu A, Wernig M, Sudhof T . Synaptogenic effect of -Swedish mutation in familial Alzheimer's disease. Sci Transl Med. 2022; 14(667):eabn9380. PMC: 9894682. DOI: 10.1126/scitranslmed.abn9380. View

5.
Bracko O, Cruz Hernandez J, Park L, Nishimura N, Schaffer C . Causes and consequences of baseline cerebral blood flow reductions in Alzheimer's disease. J Cereb Blood Flow Metab. 2021; 41(7):1501-1516. PMC: 8221770. DOI: 10.1177/0271678X20982383. View